Equities research analysts forecast that Stemline Therapeutics Inc (NASDAQ:STML) will post earnings per share (EPS) of ($0.67) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.83) to ($0.50). Stemline Therapeutics posted earnings per share of ($0.69) in the same quarter last year, which would suggest a positive year over year growth rate of 2.9%. The company is expected to report its next earnings results on Wednesday, May 8th.
According to Zacks, analysts expect that Stemline Therapeutics will report full year earnings of ($2.24) per share for the current fiscal year, with EPS estimates ranging from ($2.88) to ($1.63). For the next year, analysts anticipate that the business will post earnings of ($0.55) per share, with EPS estimates ranging from ($1.87) to $1.00. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Stemline Therapeutics.
STML has been the topic of a number of recent research reports. Piper Jaffray Companies reissued an “overweight” rating on shares of Stemline Therapeutics in a report on Wednesday, February 6th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. ValuEngine raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 4th. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Stemline Therapeutics in a report on Wednesday, December 26th. Finally, BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, December 27th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Stemline Therapeutics currently has a consensus rating of “Buy” and an average price target of $26.00.
Hedge funds have recently made changes to their positions in the stock. Hikari Power Ltd acquired a new position in Stemline Therapeutics during the fourth quarter worth $144,000. Point72 Asset Management L.P. grew its holdings in Stemline Therapeutics by 20.9% during the third quarter. Point72 Asset Management L.P. now owns 260,000 shares of the biopharmaceutical company’s stock worth $4,316,000 after acquiring an additional 45,000 shares during the period. Vanguard Group Inc. grew its holdings in Stemline Therapeutics by 1.5% during the third quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock worth $21,215,000 after acquiring an additional 18,487 shares during the period. Polar Capital LLP grew its holdings in Stemline Therapeutics by 12.1% during the fourth quarter. Polar Capital LLP now owns 2,302,666 shares of the biopharmaceutical company’s stock worth $21,875,000 after acquiring an additional 248,616 shares during the period. Finally, BlueMountain Capital Management LLC grew its holdings in Stemline Therapeutics by 175.9% during the third quarter. BlueMountain Capital Management LLC now owns 23,537 shares of the biopharmaceutical company’s stock worth $391,000 after acquiring an additional 15,006 shares during the period. 47.32% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:STML traded down $0.23 during trading on Friday, reaching $12.90. The company had a trading volume of 738,305 shares, compared to its average volume of 697,353. The firm has a market cap of $562.04 million, a P/E ratio of -4.31 and a beta of 1.14. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $20.55.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Recommended Story: What is dollar cost averaging (DCA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.